Cvt-301 for the treatment of parkinson’s disease

Danielle S. Shpiner, Sagari Bette, Daniel G. Di Luca, Jason Margolesky

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Introduction: For patients with Parkinson’s disease (PD), the treatment of motor and nonmotor fluctuations is tantamount to maintaining quality of life. Subcutaneous apomorphine has been the only commercially available rescue therapy for the treatment of OFF episodes. In December 2018, CVT-301 (Inbrija), an inhaled formulation of levodopa (LD), was approved by the FDA for this indication. Areas covered: In this review, the authors summarize the armamentarium available to address motor fluctuations in PD, including medications in development. The authors discuss the pharmacological properties of CVT-301 as well as its efficacy and safety as reported in phase I, II, and III studies. Expert opinion: More than 20 medications or surgical procedures are available or in development to address motor fluctuations in PD. Deep brain stimulation (DBS) is an invasive but effective intervention at the end of the treatment spectrum. Less invasive therapies are used in combination to ameliorate motor fluctuations. Rescue therapies can help patients taking oral medications who experience delayed onset symptom relief (delayed ON), and unexpected wearing OFF by providing rapid and durable symptoms relief. CVT-301, an inhaled LD formulation, provides a safe and effective delivery mechanism that may be preferred by patients over subcutaneous injections.

Original languageEnglish (US)
Pages (from-to)603-611
Number of pages9
JournalExpert review of neurotherapeutics
Issue number7
StatePublished - Jul 3 2019


  • CVT-301
  • Inhaled levodopa
  • Levodopa
  • Parkinson’s disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Cvt-301 for the treatment of parkinson’s disease'. Together they form a unique fingerprint.

Cite this